NSE · BSE · Real-time

Breaking Corporate Events, Analysed in Real Time

High-value corporate events — new orders, fund raises, capacity expansions, and earning calls — analysed by AI the moment they hit the exchange.

All New Order Fund Raise Expansion Earning Call Regulatory Approval Production Started Product Launched
Tagged Earning Call
GK Energy Q1 Revenue Surges 71% to ₹505 Crore; Management Eyes Revenue Doubling in FY27
Earning Call

GK Energy Q1 Revenue Surges 71% to ₹505 Crore; Management Eyes Revenue Doubling in FY27

GK Energy Limited achieved its highest-ever quarterly revenue in Q1 FY27, driven by a 122% increase in system installations. The company is leveraging an asset-light OEM model to scale its solar pump and rooftop solar segments while reducing debt using recent IPO proceeds.

GK Energy Ltd
13 Aug 2026 4 min read
NPST Reports 75% YoY Revenue Surge in Q1 FY27; Targets ₹900 Cr Revenue by FY29
Earning Call

NPST Reports 75% YoY Revenue Surge in Q1 FY27; Targets ₹900 Cr Revenue by FY29

Network People Services Technologies Ltd (NPST) delivered a strong year-on-year performance in Q1 FY27, with revenue surging 75% to ₹61.4 crore. The company is successfully pivoting from low-margin payment services to high-margin regulatory technology and international technology service provider models.

Network People Services Technologies Ltd (544396)
12 Aug 2026 5 min read
Max India Reports 66% Revenue Surge in Q1 FY27 Driven by Antara Noida Handovers
Earning Call

Max India Reports 66% Revenue Surge in Q1 FY27 Driven by Antara Noida Handovers

Max India Ltd reported a robust 66% year-on-year increase in consolidated revenue for Q1 FY27, reaching ₹68.6 crore. The growth was primarily spearheaded by the commencement of handovers at Antara Noida and a 23% sequential rise in care home occupancy.

Max India Ltd
12 Aug 2026 5 min read
Kwality Pharmaceuticals Targets ₹700 Crore Revenue in FY27 Following Guidance Revision
Earning Call

Kwality Pharmaceuticals Targets ₹700 Crore Revenue in FY27 Following Guidance Revision

Kwality Pharmaceuticals has upwardly revised its FY27 revenue guidance to over ₹700 crore, reflecting a 40 percent year-on-year growth target. The company is strategically positioning itself to double its revenue to ₹1,500 crore by FY30, driven by aggressive international registrations and the commissioning of new manufacturing facilities.

Kwality Pharmaceuticals Ltd
12 Aug 2026 5 min read
Thomas Scott (India) Reports 63% Q4 Revenue Growth Driven by Premium Digital Pivot
Earning Call

Thomas Scott (India) Reports 63% Q4 Revenue Growth Driven by Premium Digital Pivot

Thomas Scott (India) Limited achieved significant top-line expansion in Q4 FY26, marking its tenth consecutive quarter of revenue growth. This performance was driven by a strategic shift toward premium international licensed brands and a digital-first commerce model, although operational disruptions and high working capital levels remain key monitoring points.

Thomas Scott (India) Limited
11 Aug 2026 5 min read
Jyoti Resins & Adhesives Reports 17% Revenue Growth in Q1 FY27 Amid Margin Pressure
Earning Call

Jyoti Resins & Adhesives Reports 17% Revenue Growth in Q1 FY27 Amid Margin Pressure

Jyoti Resins and Adhesives Ltd reported a 17% year-on-year revenue increase to ₹877.1 million for Q1 FY27, driven by robust volume growth and price adjustments. While a 60% surge in raw material costs temporarily compressed EBITDA margins, the company expects a significant recovery in the second quarter.

Jyoti Resins & Adhesives Ltd (514448)
11 Aug 2026 4 min read
Sejal Glass Ltd Q1 Revenue Surges 53% to ₹117.95 Cr, Targets 40% Growth in FY27
Earning Call

Sejal Glass Ltd Q1 Revenue Surges 53% to ₹117.95 Cr, Targets 40% Growth in FY27

Sejal Glass Limited reported a robust start to FY27 with consolidated revenue jumping 52.88% year-on-year to ₹117.95 crore. The company is leveraging strong demand in the UAE and India while expanding its product portfolio into high-margin segments like railway and fire-rated glass.

Sejal Glass Ltd
11 Aug 2026 6 min read
Corona Remedies Reports 21.9% Q1 Revenue Growth as EBITDA Margins Hit 22%
Earning Call

Corona Remedies Reports 21.9% Q1 Revenue Growth as EBITDA Margins Hit 22%

Corona Remedies reported a strong start to FY27, significantly outperforming the Indian Pharmaceutical Market across core therapy areas. The company achieved a net profit of ₹60.11 crore while successfully commercializing its advanced Europe-GMP approved hormonal manufacturing facility to drive future international expansion.

Corona Remedies Ltd (544644)
10 Aug 2026 5 min read
Earning Call

Alembic Pharmaceuticals Q1 Revenue Jumps 26% as US Generics Surge 49% YoY

Alembic Pharmaceuticals delivered a strong Q1 FY27 performance with consolidated revenue reaching INR 2,150 Cr. The growth was spearheaded by a 49% surge in the US Generics business and a 33% increase in the API segment, leading management to raise the overall annual growth guidance.

Alembic Pharmaceuticals Ltd
10 Aug 2026 5 min read